Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.
- NavTrac and NavTrac-MR introducers submitted for FDA 510(k) clearance
- 14 of 15 FDA submissions completed for US market platform
- Recent clearances include NorthStar and Vision-MR catheters for pediatric use
- Milestone advances MRI-guided cardiac procedures in electrophysiology
- Company highlights potential for expanded US hospital adoption
Final FDA Submissions Complete 510(k) Filing Series
Imricor Medical Systems (ASX:IMR) has taken a significant regulatory stride by submitting its NavTrac and NavTrac-MR steerable introducers for FDA 510(k) clearance, bringing the company tantalisingly close to full US market approval. These introducers, essential for guiding cardiovascular catheters into the heart, complement Imricor’s growing portfolio of MRI-compatible cardiac devices.
The NavTrac is designed for use in conventional x-ray catheterisation labs, while the NavTrac-MR features MR active tracking coils tailored for interventional MRI (iMR) environments. This dual offering underscores Imricor’s strategy to replace traditional x-ray guidance with superior MRI imaging in cardiac procedures.
Building on Recent Pediatric Clearances
This submission follows the FDA’s recent green light for Imricor’s NorthStar Mapping System and Vision-MR Diagnostic Catheter for both adult and pediatric use, a key commercial milestone given the high sensitivity of children to radiation exposure during cardiac interventions. The company is reportedly advancing sales discussions with several US pediatric hospitals, which could serve as pivotal early adopters of its technology.
Imricor’s CEO Steve Wedan emphasised the compelling economics and clinical benefits of performing cardiac catheterisations in iMR labs, particularly the elimination of x-ray exposure for vulnerable pediatric patients. This approach not only promises safer procedures but may also catalyse a broader rollout across adult hospitals as the full ablation portfolio progresses through regulatory channels.
Regulatory Momentum and Market Implications
With 14 of the 15 required FDA submissions now lodged, Imricor has submitted over 50,000 pages of regulatory documentation, reflecting the complexity of reinventing the cardiac electrophysiology toolkit for MRI compatibility. Wedan described the scale of this multi-product approval process as "extremely unusual" in his 36 years in medical device development.
This near-complete regulatory platform positions Imricor to challenge the entrenched x-ray fluoroscopy standard in the US electrophysiology market, the world’s largest. The potential to establish an installed base of iMR labs today could accelerate adoption once the full ablation device suite gains clearance.
Next Steps and Market Watch
While the final FDA clearance outcome and timing for the remaining submission remain uncertain, the company’s regulatory momentum is clear. Investors and observers should monitor subsequent FDA decisions and the pace at which US hospitals integrate Imricor’s MRI-guided solutions into clinical practice, particularly in pediatric cardiology.
Bottom Line?
Imricor’s near-complete FDA submission portfolio signals a pivotal advance towards reshaping cardiac electrophysiology with MRI-guided technology in the US.
Questions in the middle?
- When will the FDA clear the final outstanding device submission?
- How quickly will US pediatric and adult hospitals adopt Imricor’s MRI-guided platform?
- What impact will MRI-guided procedures have on the economics of cardiac catheterisation?